Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

• Main Authors: Mok T., Ladrera G., Srimuninnimit V., Sriuranpong V., Yu C., Thongprasert S., Sandoval-Tan J., Lee J., Fuerte F., Shames D., Klughammer B., Truman M., Perez-Moreno P., Wu Y.
• 格式: 雜誌
• 出版: 2017
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84966701371&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/41699
• 機構: Chiang Mai University

© 2016 The Authors. Objectives: The FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further exploratory biomarker analyses were...